Batroxobin mobilizes circulating endothelial progenitor cells in patients with deep vein thrombosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 1, 2011, Pages 75-79

  Zhang, Lei ^a   Lu, Shi Hong ^a   Li, Li ^b   Tao, Yu Guo ^b   Wan, Yong Ling ^c   Senga, Hirobumi ^c   Yang, Renchi ^a   Han, Zhong Chao ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b Tianjin Union Medicine Centre   (China)

^c SINOPEC BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY   (China)

Author keywords

batroxobin; deep vein thrombosis; endothelial progenitor cells

Indexed keywords

ACETYLSALICYLIC ACID; BATROXOBIN; CD31 ANTIGEN; FIBRINOGEN; LOW MOLECULAR WEIGHT HEPARIN; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CD34 SELECTION; CELL ACTIVATION; CELL ADHESION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ENDOTHELIAL PROGENITOR CELL; ENTERIC COATED TABLET; ERYTHEMA; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEG PAIN; LEG SWELLING; LIMB SALVAGE; MALE; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL BLOOD MONONUCLEAR CELL; PHLEBOGRAPHY; PRIORITY JOURNAL; PROTHROMBIN TIME; RECANALIZATION; REPEATED DRUG DOSE; THROMBIN TIME; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BATROXOBIN; ENDOTHELIAL CELLS; FEMALE; FIBRINOLYTIC AGENTS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; STEM CELLS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 78651387050     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609347903     Document Type: Article

References (20)

1. Hennerici MG, Kay R., Bogousslavsky J., Lenzi GL, Verstraete M., Orgogozo JM, for the ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet. 2006 ; 368 (9550). 1871-1878.
2. Lochnit G., Geyer R. Carbohydrate structure analysis of batroxobin, a thrombin-like serine protease from Bothrops moojeni venom. Eur J Biochem. 1995 ; 228 (3). 805-816.
3. Tomaru T., Uchida Y., Nakamura F., Sonoki H., Tsukamoto M., Sugimoto T. Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study. Am Heart J. 1989 ; 117 (2). 275-281.
4. Latallo ZS Retrospective study on complications and adverse effects of treatment with thrombin-like enzymes-a multicentre trial. Thromb Haemost. 1983 ; 50 (2). 604-609.
5. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005 ; 365 (9465). 1163-1174.
6. Kang WS, Lim IH, Yuk DY, et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res. 1999 ; 96 (3). 229-237.
7. Yang C., Zhang ZH, Li ZJ, Yang RC, Qian GQ, Han ZC Enhancement of neovasculariazation with cord blood CD133+ cell-derived endothelial progenitor cell transplantation. Thromb Haemost. 2004 ; 91 (6). 1202-112.
8. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999 ; 85 (3). 221-228.
9. Suwaidi JA, Hamasaki S., Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000 ; 101 (9). 948-954.
10. Schächinger V., Britten MB, Zeiher AM Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000 ; 101 (16). 1899-1906.
11. Perticone F., Ceravolo R., Pujia A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001 ; 104 (2). 191-196.
12. Gokce N., Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002 ; 105 (13). 1567-1572.
13. Halcox JP, Schenke WH, Zalos G., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002 ; 106 (6). 653-658.
14. Hill JM, Zalos G., Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003 ; 348 (7). 593-600.
15. Tateishi-Yuyama E., Matsubara H., Murohara T., et al., and the Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002 ; 360 (9331). 427-435.
16. Huang PP, Li SZ, Han MZ, et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb Haemost. 2004 ; 91 (3). 606-609.
17. Santo SD, Tepper OM, von Ballmoos MW, et al. Cell-based therapy facilitates venous thrombus resolution. Thromb Haemost. 2009 ; 101 (3). 460-464.
18. Li S., Zhou B., Han ZC Therapeutic neovascularization by transplantation of mobilized peripheral blood mononuclear cells for limb ischemia. A comparison between CD34+ and CD34- mononuclear cells. Thromb Haemost. 2006 ; 95 (2). 301-311.
19. Huang PP, Yang XF, Li SZ, Wen JC, Zhang Y., Han ZC Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost. 2007 ; 98 (6). 1335-1342.
20. Wang DS, Hanamoto M., Fang F., et al. Defibrinogenating effect of batroxobin (Defibrase) in rats and inhibition of migration of human vascular smooth muscle cells by the plasma of batroxobin-treated rats in vitro. Atherosclerosis. 2001 ; 156 (1). 73-80.